# QNCX — Quince Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** QNCX  
**Sources:** 19  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-qncx-quince-therapeutics-inc-catalysts-narrative-risks-10423

---

## Important context: the ticker you asked about has already changed

As of the reference date (2026-10-31), Quince Therapeutics is no longer trading as QNCX. Per a Globe Newswire press release, Quince changed its name to **IRulya Therapeutics Inc. effective October 9, 2026**, and its common stock began trading on the Nasdaq Capital Market under the new ticker **"IRLA" effective October 12, 2026** [[1]](https://finance.yahoo.com/healthcare/articles/quince-therapeutics-relaunches-irulya-therapeutics-120000282.html). The name change followed the completion of Quince's stock-for-stock merger with privately held **Orphai Therapeutics** [[1]](https://finance.yahoo.com/healthcare/articles/quince-therapeutics-relaunches-irulya-therapeutics-120000282.html), [[9]](https://www.morningstar.com/news/globe-newswire/9810311/quince-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-update).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-qncx-quince-therapeutics-inc-catalysts-narrative-risks-10423 (free to sign up)._